Lyndra Therapeutics
Michelle O'Connor has a diverse work experience in the pharmaceutical industry. Michelle worked as an Associate Director in Analytical Research and Development at Lyndra Therapeutics since March 2022. Prior to that, they held the position of Principal Scientist from January 2021 to March 2022 at the same company. Before joining Lyndra Therapeutics, Michelle served as a Senior Scientist at Arsenal Medical from September 2018 to May 2019. Michelle also worked at Lysogene as a Manager and Scientist, specializing in Analytical Development and Technical Operations, from 2017 to 2018. Michelle started their career as a Senior Research Associate at Moderna Therapeutics and later joined Novartis Vaccines and Diagnostics, Inc. as an Associate Scientist III from April 2012 to April 2014.
Michelle O'Connor attended Wellesley College from 2004 to 2008, where they earned their Bachelor of Science degree in Analytical Chemistry. In 2011, they obtained a certification in Advanced HPLC Method Development and Validation from Waters Corporation.
Lyndra Therapeutics
Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained-release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily.